MBX Biosciences, Inc.
MBX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001776111
In the last 90 days, MBX Biosciences, Inc. insiders filed 0 open-market purchases and 1 sale; 172 institutions reported holding it in 13F filings for Q2 2026, worth $3.06B in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding MBX Biosciences, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 88 | 118 | +30 |
| Shares | 36.8M | 47.8M | +11.0M (+29.7%) |
| Value | $420.3M | $836.4M | +$416.0M (+99.0%) |
New holders (39)
Institutions that held MBX Biosciences, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
Sold out (9)
Institutions that held MBX Biosciences, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| MPM Oncology Impact Management LP | 1,294,416 | $14.8M |
| Ra Capital Management, L.P. | 377,841 | $4.31M |
| Sio Capital Management, LLC | 241,000 | $2.75M |
| Resolute Capital Asset Partners LLC | 49,670 | $566.7K |
| Susquehanna International Group, LLP | 27,632 | $315.3K |
| Prelude Capital Management, LLC | 15,617 | $178.2K |
| Intech Investment Management LLC | 14,271 | $162.8K |
| Raymond James Financial Inc | 761 | $8.68K |
| Simplex Trading, LLC | 411 | $4.00K |